Fcy receptors are required for NF-kB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease

Molecular Neurodegeneration

Volumn 5, Issue 1, 2010, Pages

  Cao, Shuwen ^a   Theodore, Shaji ^a   Standaert, David G ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; FC RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TRANSCRIPTION FACTOR RELA; TYROSINE 3 MONOOXYGENASE;

ADAPTIVE IMMUNITY; ADENOVIRUS 2; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; SEROTYPE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; WILD TYPE;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

EID: 77958132307     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-5-42     Document Type: Article

References (35)

1. Alpha-Synuclein in Lewy Bodies. MG Spillantini ML Schmidt VM Lee JQ Trojanowski R Jakes M Goedert, Nature 1997 388 839 840 10.1038/42166 9278044
2. Genetics of Parkinson's disease and parkinsonism. J Hardy H Cai MR Cookson K Gwinn-Hardy A Singleton, Ann Neurol 2006 60 389 98 10.1002/ana.21022 17068789
3. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. R Kruger AM Vieira-Saecker W Kuhn D Berg T Muller N Kuhnl GA Fuchs A Storch M Hungs D Woitalla H Przuntek JT Epplen L Schols O Riess, Ann Neurol 1999 45 611 7 10.1002/1531-8249(199905)45: 5<611::AID-ANA93.0.CO;2-X 10319883
4. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. MH Polymeropoulos C Lavedan E Leroy SE Ide A Dehejia A Dutra B Pike H Root J Rubenstein R Boyer ES Stenroos S Chandrasekharappa A Athanassiadou T Papapetropoulos WG Johnson AM Lazzarini RC Duvoisin G Di Iorio LI Golbe RL Nussbaum, Science 1997 276 2045 7 10.1126/science.276.5321.2045 9197268
5. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. PL McGeer S Itagaki BE Boyes EG McGeer, Neurology 1988 38 1285 91 3399080
6. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. W Zhang T Wang Z Pei DS Miller X Wu ML Block B Wilson W Zhang Y Zhou JS Hong J Zhang, The FASEB J 2005 19 533 542 10.1096/fj.04-2751com (Pubitemid 40471244)
7. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) induced Parkinson's disease mice model. A Czlonkowska M Kohutnicka I Kurkowska-Jastrzebska A Czlonkowski, Neurodegeneration 1996 5 137 143 10.1006/neur.1996.0020 8819134
8. Reactive microgliosis participates in MPP+-induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor. T Wang W Zhang Z Pei M Block B Wilson JM Reece DS Miller JS Hong, Faseb J 2006 20 906 915 10.1096/fj.05-5053com 16675848
9. Toxin-induced models of Parkinson's disease. J Bove D Prou C Perier S Przedborski, NeuroRx 2005 2 484 494 10.1602/neurorx.2.3.484 16389312
10. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. Y Liu L Qin G Li W Zhang L An B Liu JS Hong, J Pharmacol Exp Ther 2003 305 212 218 10.1124/jpet.102.043166 12649371
11. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. DC Wu V Jackson-Lewis M Vila K Tieu P Teismann C Vadseth DK Choi H Ischiropoulos S Przedborski, J Neurosci 2002 22 1763 1771 11880505
12. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. V Brochard B Combadière A Prigent Y Laouar A Perrin V Beray-Berthat O Bonduelle D Alvarez-Fischer J Callebert JM Launay C Duyckaerts RA Flavell EC Hirsch S Hunot, J Clin Invest 2009 119 1 182 92 19104149
13. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. S Theodore S Cao PJ McLean DG Standaert, J Neuropathol Exp Neurol 2008 67 12 1149 58 10.1097/NEN.0b013e31818e5e99 19018246
14. Fc receptor biology. M Daeron, Annu Rev Immunol 1997 15 203 234 10.1146/annurev.immunol.15.1.203 9143687
15. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. CF Orr DB Rowe Y Mizuno H Mori GM Halliday, Brain 2005 128 2665 2674 10.1093/brain/awh625 16219675
16. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. W Le D Rowe W Xie I Ortiz Y He SH Appel, J Neurosci 2001 21 8447 8455 11606633
17. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. S Chen WD Le WJ Xie ME Alexianu JI Engelhardt L Siklos SH Appel, Arch Neurol 1998 55 1075 1080 10.1001/archneur.55.8.1075 9708957
18. Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Y He WD Le SH Appel, Exp Neurol 2002 176 322 327 10.1006/exnr.2002.7946 12359173
19. Stimulation of Fc gamma R receptors induces monocyte chemoattractant protein-1 in the human monocytic cell line THP-1 by a mechanism involving I kappa B-alpha degradation and formation of p50/p65 NF-kappa B/Rel complexes. A Alonso Y Bayán M Renedo MS Crespo, Int Immunol 2000 12 4 547 54 10.1093/intimm/12.4.547 10744656
20. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. L Vermeulen G De Wilde S Notebaert W Vanden Berghe G Haegeman, Biochem Pharmacol 2002 64 5-6 963 70 10.1016/S0006-2952(02)01161-9 12213593
21. Signaling to NF-kappaB. MS Hayden S Ghosh, Genes Dev 2004 18 18 2195 224 10.1101/gad.1228704 15371334
22. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. A Ghosh A Roy X Liu JH Kordower EJ Mufson DM Hartley S Ghosh RL Mosley HE Gendelman K Pahan, Proc Natl Acad Sci USA 2007 104 47 18754 9 10.1073/pnas.0704908104 18000063
23. FcR Chain Deletion results in Pleiotrophic Effector Cell Defects. T Takai M Li D Sylvestre R Clynes J Ravetch, Cell 1994 76 3 519 29 10.1016/0092- 8674(94)90115-5 8313472
24. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. S Zolotukhin BJ Byrne E Mason I Zolotukhin M Potter K Chesnut C Summerford RJ Samulski N Muzyczka, Gene Ther 1999 6 973 985 10.1038/sj.gt.3300938 10455399
25. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. A Auricchio M Hildinger E O'Connor GP Gao JM Wilson, Hum Gene Ther 2001 12 71 76 10.1089/104303401450988 11177544
26. NF-kappaB regulates thrombin-induced ICAM-1 gene expression in cooperation with NFAT by binding to the intronic NF-kappaB site in the ICAM-1 gene. J Xue PB Thippegowda G Hu K Bachmaier JW Christman AB Malik C Tiruppathi, Physiol Genomics 2009 38 1 42 53 10.1152/physiolgenomics.00012.2009 19351910
27. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of Parkinson's disease. DC Wu P Teismann K Tieu M Vila V Jackson-Lewis H Ischiropoulos S Przedborski, Proc Natl Acad Sci USA 2003 100 6145 6150 10.1073/pnas.0937239100 12721370
28. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. JL St Martin J Klucken TF Outeiro P Nguyen C Keller-McGandy I Cantuti-Castelvetri TN Grammatopoulos DG Standaert BT Hyman PJ McLean, J Neurochem 2007 100 6 1449 57 17241127
29. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. V Sanchez-Guajardo F Febbraro D Kirik M Romero-Ramos, PLoS One 2010 5 1 8784. 10.1371/journal.pone.0008784 20098715
30. Genetic mouse models of parkinsonism: strengths and limitations. SM Fleming PO Fernagut MF Chesselet, NeuroRx 2005 2 3 495 503 10.1602/neurorx.2.3. 495 16389313
31. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced parkinsonism. AS Mandir S Przedborski V Jackson-Lewis ZQ Wang CM Simbulan-Rosenthal ME Smulson BE Hoffman DB Guastella VL Dawson TM Dawson, Proc Natl Acad Sci USA 1999 96 5774 9 10.1073/pnas.96.10. 5774 10318960
32. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. S Przedborski H Ischiropoulos, Antioxid Redox Signal 2005 7 685 93 10.1089/ars.2005.7.685 15890013
33. Requirement of the Fc receptor common gamma-chain for gamma delta T cell-mediated promotion of murine experimental autoimmune encephalomyelitis. AJ Szalai X Hu C Raman SR Barnum, Eur J Immunol 2005 35 12 3487 92 10.1002/eji.200535285 16278814
34. Activators and target genes of Rel/NF-kappaB transcription factors. HL Pahl, Oncogene 1999 18 49 6853 66 10.1038/sj.onc.1203239 10602461
35. The involvement of NF-kappaB p65/p52 in the effects of GDNF on DA neurons in early PD rats. JP Cao HJ Wang JK Yu HM Liu DS Gao, Brain Res Bull 2008 76 5 505 11 10.1016/j.brainresbull.2008.03.007 18534259